Millions of Medicare beneficiaries with obesity will gain access to GLP-1 medications through Part D for the first time in two decades when a new federal demonstration launches on July 1, 2026. The Centers for Medicare & Medicaid Services (CMS) is running the Medicare GLP-1 Bridge, a time-limited program that will cover certain GLP-1 drugs through December 31, 2027. The program breaks a statutory wall that has blocked Medicare from paying for weight-loss medications since the Part D benefit took effect in 2006.
A 20-year ban on obesity drugs and the law behind it
The legal barrier dates to the creation of the Part D prescription drug benefit itself. The statute defining which drugs qualify for Part D coverage cross-references Medicaid exclusion rules under Section 1860D-2 of the Social Security Act, which bars coverage for agents used for anorexia, weight loss, or weight gain. That single clause has kept every anti-obesity medication off Part D formularies for roughly 20 years, even as the FDA approved a growing list of effective treatments and private insurers began covering them.
The GLP-1 Bridge does not repeal that statutory exclusion. Instead, CMS structured it as a demonstration, sidestepping the need for congressional action. The program gives the agency a controlled window to test broader access while generating real-world data on costs, outcomes, and utilization. For beneficiaries, the practical result is the same: Part D plans will, for the first time, fill prescriptions for GLP-1 drugs prescribed specifically for obesity, so long as those drugs meet the demonstration’s eligibility criteria.
One wrinkle complicates the picture. Tirzepatide, marketed as Zepbound, already holds FDA approval as the first medication approved for obstructive sleep apnea in adults with obesity. Because that indication treats a recognized disease rather than weight loss alone, Part D plans can cover tirzepatide for obstructive sleep apnea patients under ordinary rules, no Bridge required. Type 2 diabetes prescriptions for GLP-1 drugs also remain eligible for standard Part D coverage. The Bridge therefore matters most for beneficiaries whose primary diagnosis is obesity itself, without an accompanying obstructive sleep apnea or diabetes diagnosis that would unlock existing coverage.
How the Bridge window could reshape Part D data
The 18-month demonstration creates a natural experiment. CMS will be able to compare tirzepatide utilization among three distinct patient groups: those prescribed the drug for type 2 diabetes under regular Part D rules, those prescribed it for obstructive sleep apnea under regular Part D rules, and those who gain access solely through the Bridge for obesity. Differences in prescribing rates, adherence, cost per beneficiary, and downstream health spending across these cohorts would give the agency concrete evidence to weigh when deciding whether to seek a permanent statutory change.
That data trail is the Bridge’s most consequential feature. CMS has not published projected enrollment or spending figures for the demonstration, and no official Part D plan bid instructions or formulary templates for the 2026–2027 period have been released. Without those details, the scale of the program remains uncertain. But the administrative claims data that Part D plans generate automatically will capture every fill, every diagnosis code, and every dollar spent, building a detailed picture of how GLP-1 coverage for obesity affects real-world care.
For clinicians, CMS has begun outlining operational details in its information for providers, including eligibility criteria, documentation expectations, and the need to record obesity-related diagnoses accurately. That guidance will shape how primary care physicians and specialists integrate GLP-1 prescribing into routine visits, from initial assessments to follow-up monitoring for side effects and weight trajectories.
Part D sponsors, meanwhile, are preparing for the demonstration under CMS’s information for Part D plans. Plans will have to decide how to design formularies, prior authorization criteria, and tier placement for covered GLP-1 products within the constraints of the Bridge. Those choices will influence which beneficiaries actually gain access, how quickly, and at what out-of-pocket cost.
Implications for beneficiaries and the future of coverage
For individual beneficiaries living with obesity, the demonstration offers a new, if temporary, pathway to medications that have often been financially out of reach. GLP-1 therapies can cost hundreds to more than a thousand dollars per month at list prices, leaving many older adults to forgo treatment when Medicare does not pay. Under the Bridge, covered beneficiaries will still face standard Part D cost sharing, but the basic hurdle of coverage will be lowered.
The limited duration of the program raises difficult questions about continuity of care. Patients who start GLP-1 therapy in late 2027 could see coverage end abruptly when the demonstration expires, unless Congress acts or CMS identifies another lawful pathway. Clinicians and plans may need to counsel patients about this uncertainty when initiating treatment, balancing near-term health gains against potential long-term affordability challenges.
Policymakers will be watching the demonstration’s results closely. If CMS can show that broader GLP-1 access for obesity leads to fewer hospitalizations, lower cardiovascular events, or reduced disability over time, the case for revisiting the underlying statutory exclusion will strengthen. Conversely, if spending surges without clear offsetting savings or health gains, lawmakers may be reluctant to open the Part D benefit permanently to weight-loss drugs.
In the meantime, the GLP-1 Bridge marks a significant, if provisional, shift in Medicare’s approach to obesity. By testing coverage within a defined window and collecting robust data, CMS is turning a long-standing legal barrier into an opportunity to measure how modern obesity pharmacotherapy performs when scaled to a national insurance program for older adults and people with disabilities.
